The GLP-1 RA should be considered for patients with CCS who do not have diabetes but are overweight or obese (BMI > 27 kg/m2), as it has been shown in the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) trial to reduce the risk of cardiovascular mortality or stroke [1,18]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.